The CDT1 (Chromatin Licensing and DNA Replication Factor 1) antibody is a critical tool in studying DNA replication regulation and cell cycle progression. CDT1 is a conserved protein essential for initiating DNA replication by loading the minichromosome maintenance (MCM) complex onto origins during the G1 phase. Its activity is tightly regulated to prevent re-replication, primarily through interactions with CDC6 and inhibition by Geminin during S/G2 phases. Dysregulation of CDT1 is linked to genomic instability, tumorigenesis, and developmental disorders, making it a focus in cancer research.
CDT1 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to quantify protein expression, assess cell cycle status, and study replication licensing mechanisms. In cancer studies, elevated CDT1 levels are associated with aggressive tumor behavior and poor prognosis, suggesting its potential as a diagnostic or prognostic biomarker. These antibodies also aid in exploring replication stress responses and the effects of therapeutic agents targeting DNA replication.
Researchers rely on CDT1 antibodies to investigate cell cycle checkpoints, replication origin licensing, and the interplay between replication proteins and oncogenic signaling pathways. Validated antibodies with high specificity are crucial to avoid cross-reactivity with homologous proteins, ensuring accurate interpretation of experimental results in both basic and translational research contexts.